co nyse qqq
well-posit growth split
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
innov cultur strong financi commit
develop next gener drug set compani apart
peer fuel long-term growth follow steep
patent cliff lilli growth prospect improv
compani launch sever new blockbust patent loss
fade
lilli intern pipelin well posit mitig patent
loss next decad compani tend spend
sale financ develop effort new drug
much higher midteen industri averag robust
pipelin result lilli strong commit research
believ recent approv diabet drug trulic tradjenta
jardianc immunolog drug taltz olumi hold
highest sale potenti lilli new drug also sever lilli
cancer drug cyramza verzenio develop
blockbust addit clinic data hold
lilli strong entrench insulin product also help
compani deal patent loss unlik tradit drug
lilli insulin drug hard copi gener creat
barrier entri noninsulin produc larg
up-front invest need creat scale effici
lilli longer-act biosimilar insulin help compani
secur market share
compani take hard look bottom line
combin cost save expect top-lin growth lilli
aim reach oper margin believ
achiev lilli expect increas gross margin
product initi greater capac util may
prove challeng patent expir high-margin
ciali alimta certain market
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
eli lilli pharmaceut compani focu neurosci
endocrinolog oncolog immunolog lilli key product includ
alimta cancer forteo osteoporosi jardianc trulic humalog
humulin diabet taltz olumi immunolog ciali
erectil dysfunct
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
rais fair valu estim
per share base strong outlook split
anim health busi continu strong gain
sever new product includ trulic
compani abil expand oper margin look
promis divest anim health busi
overal compani look well-posit drive top-lin
growth project annual sale increas
next decad result new drug launch offset
patent loss particular outlook immunolog
drug taltz olumi look strong clinic data
support drug becom leader immunolog
outsid immunolog expect diabet drug jardianc
trulic along cancer drug cyramza becom
increasingli import driver cash flow particular
jardianc look pois hit peak sale project
billion report boehring ingelheim base
valuat cost control increasingli think lilli
abl meet estim achiev oper
margin
close
improv outcom oper
cost control depend new revenu associ
success recent launch drug pipelin
expect lilli reach goal addit estim
weight cost capit lilli line
larg base low volatil cash flow
divers inelast product portfolio rate lilli
uncertainti medium larg line
pharma peer group howev lilli slightli
uncertainti partli high product concentr
risk surround compani pipelin recent
launch drug repres one fifth sale
end next year scenario analysi
assum base-cas fair valu estim bull
case probabl bear case
probabl project fair valu estim rel
base case scenario analysi show moder
varianc henc medium uncertainti rate factor
affect scenario analysi includ degre
success brand drug pipelin magnitud
market pressur current market drug larg
amount valuat driven pipelin success
new drug launch clinic trial amplifi
impact lilli valuat
patent economi scale power distribut
drug carri strong price power enabl firm
gener return invest capit excess cost
capit patent give compani time
develop next gener drug gener
mean compani top drug repres moder
amount total sale largest drug trulic
repres total sale set manag
cash flow declin new product mitig gener
competit also lilli oper structur allow
cost-cut patent loss reduc margin
pressur lost high-margin drug sale overal lilli
establish product line creat enorm cash flow
need fund averag million develop
cost per new drug addit compani power
distribut network set compani strong partner
smaller drug compani lack lilli resourc lilli
entrench insulin franchis creat ad layer
competit advantag
competit seem mani year away due complex
gain gener approv insulin high cost
build need economi scale insulin product
hurdl tradit small molecul biosimilar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
managed-car organ pharmaci benefit
manag consolid past decad
use grow size demand lower drug price
reduc coverag less innov drug forc drug
firm push true innov reduc power
lilli distribut network govern
evalu compar effect program
aggress price negoti rais bar futur
innov lilli sever headwind pipelin
hold sever biolog drug hold much stronger
competit advantag tradit small molecul
compani pipelin focus
innov treatment area unmet medic need
payer coverag price power remain strong
outsid pipelin compani strong insulin franchis
sale carri extra protect award
biolog economi scale need produc
rel lower-pr drug
gain market share follow eventu patent loss
given deceler patent loss strong pipelin
believ moat trend stabl next three
year compani key patent loss includ erectil
dysfunct drug ciali osteoporosi drug forteo
potenti cancer drug alimta patent loss
next three year affect close total sale
compani strong pipelin combin stabl current
market drug lead annual revenu
growth period pipelin side
expect billion peak annual sale psoriasi
drug taltz rheumatoid arthriti drug olumi also
strong cardiovascular data lilli diabet drug
jardianc approv drive drug peak
annual sale billion
macro environ lilli sever headwind
make solid strateg move address challeng
neg side risk-sensit food drug
administr gener approv safe drug
drug high-ne area cancer also
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
olilli launch new immunolog drug taltz
olumi offer better efficaci stronger
safeti profil tnf drug like set
olilli recent divestitur anim healthcar group
enabl firm focu higher-margin
olilli increas focu develop drug
unmet medic indic neurolog oncolog
strategi improv success rate
food drug administr drive strong price
olilli lag immuno-oncolog market may
creat competit headwind older cancer
osever lilli recent launch diabet drug
year behind competit launch
lack differenti could slow market share
oth alimta composit matter patent expir
could bring gener market
weaker patent expir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
strong cash flow deriv stabl diversifi
product portfolio remain solid financi foot
expect compani debt/ebitda level fall
project level close time close
time also expect debt/capit ratio fall
close cash flow
accru year strong growth prospect
expect lilli need make major acquisit
drive growth nevertheless expect
acquisit augment growth compani
adjust free
gener
gener revolv adjust
commit
gener
manufactur brand-nam drugmak also
govern managed-car organ continu
consolid purchas power exert price
challeng liabil lawsuit patent risk
cancer drug alimta sale elev
patent strong composit matter patent
increas likelihood earlier-than-expect gener
competit also strong data novo new drug
like weigh growth prospect trulic overal
rate compani uncertainti medium
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
view lilli stewardship rel standard
believ lilli use billion acquir imclon
like gener good return partnership
boehring ingelheim greatli improv strateg
outlook compani verdict still regard
lilli decis spend industry-lead amount
capit percentag sale research
develop pipelin look strong phase
data need determin return invest
lilli purchas price novarti anim healthcar
busi billion appear high increas
entrench anim health increas lilli competit
advantag well-posit industri spin-off
busi like benefit novarti asset
januari dave rick took helm
ceo follow smooth transit previou ceo
john lechleit retir rick bring strong experi
previous serv presid lilli biomedicin
group cover alzheim diseas urolog
immunolog musculoskelet diseas pain well
compani global market function rick
experi lilli date back join
compani busi develop associ dont
expect major chang transit senior
ceo/chairman board/
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
lilli post solid long-term outlook look solid
guidanc slightli weak feb
report fourth-quart result slightli ahead
consensu expect compani also
lower full-year guidanc expect
partli due fail lartruvo studi increas
research develop spend associ
loxo acquisit howev expect signific
chang fair valu estim base result
guidanc continu view lilli wide moat strong
posit lead number recent launch drug
late-stag pipelin asset propel industri
lead growth next five year
outlook dampen loxo
spend lartruvo failur mani recent launch
drug post signific gain set compani
strong long-term growth lilli biggest drug trulic
diabet drug repres sale post
year-over-year growth expect continu growth
trulic slower pace competit novo
increas like oral launch semaglutid late
new patient may find compel
post growth ahead expect
believ drug well posit take share
psoriasi market base lead efficaci older tnf
drug like enbrel addit sever recent
immunolog drug olumi migrain drug emgal
pipelin side lilli continu make solid stride
remain bullish near term pain drug
tanezumab hold strong efficaci along
believ manag side effect patient
limit option manag pain expect remain
pivot studi complet potenti approv
addit lilli provid updat guidanc elanco
divestitur compani expect offer exchang
lilli sharehold elanco share similar way
divest anim health busi zoeti continu
view lead anim health compani well
posit competit moat base intang
asset cost advantag
complet review lilli pipelin current
market portfolio pleas see annual pipelin report
annual drug pipelin report moat remain secur
innov counter price gener headwind
lilli announc loxo acquisit gain
cancer drug chang fair valu estim jan
announc acquisit loxo oncolog
billion expect major chang fair
valu estim base deal expect revenu
acquir cancer drug offset purchas price
increas expenditur strateg deal
bring lilli target cancer drug focus tumor
mutat trk ret btk fit well
lilli strong posit oncolog alreadi approv
cancer drug deal help fill lilli late-stag
competit advantag wide moat strengthen
portfolio drug carri strong price power loxo
approv drug vitrakvi price close
per annual cours treatment
target smaller patient group strong efficaci
drug support continu price power robust
sale vitrakvi follow-on drug partner
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
bayer close split profit drug
target trk posit cancer solid tumor
expect peak annual sale close billion loxo
late-stag drug target cancer ret fusion
lung cancer higher rate thyroid cancer
drug alreadi shown strong data non-smal cell
lung cancer respons rate refractori
patient popul alreadi taken three
therapi averag project drug reach peak
sale million annual potenti
registr phase ii data like late drug could
reach market addit loxo last later
stage drug target cancer btk mutat
ascrib sale potenti drug
early-stag data expect later
lilli investor day reinforc steadi outlook
current pipelin drug expect dec
investor day provid guidanc updat
pipelin larg match expect
expect major chang fair valu estim
moat rate continu view lilli fairli valu
compani strong stride research
develop continu support wide moat rate
heavili base abil creat next
gener innov drug carri strong price
overal view lilli strong posit diabet pain
immunolog support sever upcom data
point lead earn per share compound
annual growth rate next three year
diabet expect trulic label gain posit
cardiovascular data help defend
franchis novo competit drug longer term
provid
differenti efficaci diabet drug potenti
drug
launch late
launch cgrp migrain drug emgal competit
class group whole see rapid uptak
expect acut migrain drug lasmiditan gain approv
base strong late-stag data also expect
posit phase efficaci data ngf pain drug tanezumab
accept side effect profil
turn immunolog expect continu growth
taltz olumi driven new indic studi
head-to-head studi taltz versu tremfya
report expect endpoint
enabl taltz show superior due fast onset
action taltz remind similar drug taltz novarti
cosentyx anoth fail efficaci versu tremfya
time endpoint week also
expect posit data olumi atop dermat
set anoth growth avenu drug
led divers set new drug lilli post strong
pois steadi long-term growth
report third-quart result slightli ahead
consensu expect expect
signific chang fair valu estim
continu view stock fairli valu lilli post
strong earn growth quarter driven
top-lin growth lower expens percentag
sale believ growth larg factor
stock strong growth new product offset
declin older drug help support view
innov remain strong lilli continu reinforc
wide moat rate firm
divers group product led lilli strong growth
patent loss like slow growth key growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
driver lilli diabet drug trulic
repres compani largest drug total sale
expect drug continu grow due
under-penetrated diabet market competit novo
like caus trulic growth rate moder
also immunolog drug taltz olumi diabet drug
jardianc cancer drug verzenio show robust
growth signal one divers set growth
driver pharma growth driver
off-set gener pressur erectil dysfunct drug
ciali intensifi later year
solid expens manag strong pipelin set lilli
steadi long-term growth lilli oper
guidanc look increasingli achiev
caus amplifi growth rate bottom line
oper margin close also
lilli pipelin hold new potenti blockbust
 /posit
recommend europ lasmiditan like approv
pain tanezumab phase data well
new indic sever drug especi trulic
posit cardiovascular outcom base rewind
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
